Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Maurizio D'Incalci
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Living Beings
Disorders
Physiology
Procedures
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
51
Erba, Eugenio
48
Broggini, Massimo
36
Zucchetti, Massimo
23
Sessa, Cristiana
22
Faircloth, Glynn
20
Ubezio, Paolo
17
Jimeno, José
15
Giavazzi, Raffaella
13
Frapolli, Roberta
13
Marchini, Sergio
12
Cavalli, Franco
12
Colombo, Tina
10
Bonfanti, M
10
Damia, Giovanna
10
Geroni, Cristina
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Maurizio D'Incalci (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Cesca Marta; Frapolli Roberta; Berndt Alexander; Scarlato Valentina; Richter Petra; Kosmehl Hartwig; D'Incalci Maurizio; Ryan Anderson J; Giavazzi Raffaella
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Neoplasia (New York, N.Y.) 2009;11(11):1155-64.
-
2009: Damia Giovanna; D'Incalci Maurizio
Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
European journal of cancer (Oxford, England : 1990) 2009;45(16):2768-81.
-
2009: Sala Federica; Zucchetti Massimo; Bagnati Renzo; D'Incalci Maurizio; Pace Silvia; Capocasa Francesca; Marangon Elena
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(27):3118-26.
-
2009: Rizzo Angela; Salvati Erica; Porru Manuela; D'Angelo Carmen; Stevens Malcolm F; D'Incalci Maurizio; Leonetti Carlo; Gilson Eric; Zupi Gabriella; Biroccio Annamaria
Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway.
Nucleic acids research 2009;37(16):5353-64.
-
2009: Mertens Fredrik; Antonescu Cristina R; Hohenberger Peter; Ladanyi Marc; Modena Piergiorgio; D'Incalci Maurizio; Casali Paolo G; Aglietta Massimo; Alvegård Thor
Translocation-related sarcomas.
Seminars in oncology 2009;36(4):312-23.
-
2009: Grosso F; Sanfilippo R; Virdis E; Piovesan C; Collini P; Dileo P; Morosi C; Tercero J C; Jimeno J; D'Incalci M; Gronchi A; Pilotti S; Casali P G
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1439-44.
-
2009: Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
European journal of cancer (Oxford, England : 1990) 2009;45(12):2116-22.
-
2009: Ubezio Paolo; Lupi Monica; Branduardi Davide; Cappella Paolo; Cavallini Edoardo; Colombo Valentina; Matera Giada; Natoli Claudia; Tomasoni Daniela; D'Incalci Maurizio
Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities.
Cancer research 2009;69(12):5234-40.
-
2009: Forni Claudia; Minuzzo Mario; Virdis Emanuela; Tamborini Elena; Simone Matteo; Tavecchio Michele; Erba Eugenio; Grosso Federica; Gronchi Alessandro; Aman Pierre; Casali Paolo; D'Incalci Maurizio; Pilotti Silvana; Mantovani Roberto
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Molecular cancer therapeutics 2009;8(2):449-57.
-
2009: D'Incalci Maurizio
Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?
European journal of cancer (Oxford, England : 1990) 2009;45(3):316-7.
-
2008: Marchini Sergio; Mariani Pietro; Chiorino Giovanna; Marrazzo Eleonora; Bonomi Riccardo; Fruscio Robert; Clivio Luca; Garbi Annalisa; Torri Valter; Cinquini Michela; Dell'Anna Tiziana; Apolone Giovanni; Broggini Massimo; D'Incalci Maurizio
Analysis of gene expression in early-stage ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7850-60.
-
2008: Leonetti Carlo; Scarsella Marco; Riggio Giuseppe; Rizzo Angela; Salvati Erica; D'Incalci Maurizio; Staszewsky Lidia; Frapolli Roberta; Stevens Malcolm F; Stoppacciaro Antonella; Mottolese Marcella; Antoniani Barbara; Gilson Eric; Zupi Gabriella; Biroccio Annamaria
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7284-91.
-
2008: Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Role of homologous recombination in trabectedin-induced DNA damage.
European journal of cancer (Oxford, England : 1990) 2008;44(4):609-18.
-
2008: Marangon Elena; Sala Federica; Caffo Orazio; Galligioni Enzo; D'Incalci Maurizio; Zucchetti Massimo
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Journal of mass spectrometry : JMS 2008;43(2):216-23.
-
2007: Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Cell proliferation 2007;40(6):885-904.
-
2007: Salvati Erica; Leonetti Carlo; Rizzo Angela; Scarsella Marco; Mottolese Marcella; Galati Rossella; Sperduti Isabella; Stevens Malcolm F G; D'Incalci Maurizio; Blasco Maria; Chiorino Giovanna; Bauwens Serge; Horard Béatrice; Gilson Eric; Stoppacciaro Antonella; Zupi Gabriella; Biroccio Annamaria
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect.
The Journal of clinical investigation 2007;117(11):3236-47.
-
2007: Paulis Marianna; Bensi Mirella; Orioli Donata; Mondello Chiara; Mazzini Giuliano; D'Incalci Maurizio; Falcioni Cristiano; Radaelli Enrico; Erba Eugenio; Raimondi Elena; De Carli Luigi
Transfer of a human chromosomal vector from a hamster cell line to a mouse embryonic stem cell line.
Stem cells (Dayton, Ohio) 2007;25(10):2543-50.
-
2007: Damia Giovanna; D'Incalci Maurizio
Targeting DNA repair as a promising approach in cancer therapy.
European journal of cancer (Oxford, England : 1990) 2007;43(12):1791-801.
-
2007: Grosso Federica; Jones Robin L; Demetri George D; Judson Ian R; Blay Jean-Yves; Le Cesne Axel; Sanfilippo Roberta; Casieri Paola; Collini Paola; Dileo Palma; Spreafico Carlo; Stacchiotti Silvia; Tamborini Elena; Tercero Juan Carlos; Jimeno Josè; D'Incalci Maurizio; Gronchi Alessandro; Fletcher Jonathan A; Pilotti Silvana; Casali Paolo G
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
The lancet oncology 2007;8(7):595-602.
-
2007: D'Incalci Maurizio
Nitrosoureas: molecular pharmacology/ translational research.
Tumori 2007;93(3):suppl 17-21.
-
2007: D'Incalci Maurizio; Steward William P; Gescher Andreas J
Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?
Cancer treatment reviews 2007;33(3):223-9.
-
2007: Bianchi Roberto; Gilardini Alessandra; Rodriguez-Menendez Virginia; Oggioni Norberto; Canta Annalisa; Colombo Tina; De Michele Giulia; Martone Sara; Sfacteria Alessandra; Piedemonte Giuseppe; Grasso Giovanni; Beccaglia Patrizia; Ghezzi Pietro; D'Incalci Maurizio; Lauria Giuseppe; Cavaletti Guido
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth.
European journal of cancer (Oxford, England : 1990) 2007;43(4):710-7.
-
2007: Cavaletti Guido; Gilardini Alessandra; Canta Annalisa; Rigamonti Laura; Rodriguez-Menendez Virginia; Ceresa Cecilia; Marmiroli Paola; Bossi Mario; Oggioni Norberto; D'Incalci Maurizio; De Coster Roland
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Experimental neurology 2007;204(1):317-25.
-
2007: Sessa C; Cresta S; Cerny T; Baselga J; Rota Caremoli E; Malossi A; Hess D; Trigo J; Zucchetti M; D'Incalci M; Zaniboni A; Capri G; Gatti B; Carminati P; Zanna C; Marsoni S; Gianni L
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):561-8.
-
2007: Di Francesco Angela Maria; Meco Daniela; Torella Anna Rita; Barone Giuseppe; D'Incalci Maurizio; Pisano Claudio; Carminati Paolo; Riccardi Riccardo
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
Biochemical pharmacology 2007;73(5):643-55.
-
2007: Gambacorti-Passerini Carlo B; Tornaghi Lucia; Marangon Elena; Franceschino Anna; Pogliani Enrico M; D'Incalci Maurizio; Zucchetti Massimo
Imatinib concentrations in human milk.
Blood 2007;109(4):1790.
-
2007: D'Incalci M; Brunelli D; Marangon E; Simone M; Tavecchio M; Gescher A; Mantovani R
Modulation of gene transcription by natural products--a viable anticancer strategy.
Current pharmaceutical design 2007;13(27):2744-50.
-
2006: Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(12):2028-35.
-
2006: Fruscio Robert; Lissoni Andrea A; Frapolli Roberta; Corso Silvia; Mangioni Costantino; D'Incalci Maurizio; Zucchetti Massimo
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
Cancer chemotherapy and pharmacology 2006;58(3):319-25.
-
2006: Biroccio Annamaria; Rizzo Angela; Elli Raffaella; Koering Catherine-Elaine; Belleville Aurélie; Benassi Barbara; Leonetti Carlo; Stevens Malcolm F G; D'Incalci Maurizio; Zupi Gabriella; Gilson Eric
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells.
European journal of cancer (Oxford, England : 1990) 2006;42(12):1881-8.
-
2006: Grosso F; Dileo P; Sanfilippo R; Stacchiotti S; Bertulli R; Piovesan C; Jimeno J; D'Incalci M; Gescher A; Casali P G
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1484-90.
-
2006: Gerhauser Clarissa; Bartsch Helmut; Crowell James; De Flora Silvio; D'Incalci Maurizio; Dittrich Christian; Frank Norbert; Mihich Enrico; Steffen Christian; Tortora Giampaolo; Gescher Andreas
Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005.
European journal of cancer (Oxford, England : 1990) 2006;42(10):1338-43.
-
2006: D'Incalci Maurizio
Correlation of ErbB2 gene status, mRNA and protein expression.
Onkologie 2006;29(6):246-7.
-
2006: Mondello Chiara; Zongaro Samantha; D'Incalci Maurizio
Telomerase expression in somatic cells: fountain of youth or Damocles' sword?
Cell cycle (Georgetown, Tex.) 2006;5(5):465-6.
-
2006: Smyth John; Verweij Jaap; D'Incalci Maurizio; Balakrishnan Lekshmy
"The Art of Successful Publication" ECCO 13 workshop report.
European journal of cancer (Oxford, England : 1990) 2006;42(4):434-6.
-
2006: Rizzari Carmelo; Citterio Marco; Zucchetti Massimo; Conter Valentino; Chiesa Robert; Colombini Antonella; Malguzzi Silvia; Silvestri Daniela; D'Incalci Maurizio
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Haematologica 2006;91(1):24-31.
-
2006: Verschoyle Richard D; Greaves Peter; Cai Hong; Borkhardt Arndt; Broggini Massimo; D'Incalci Maurizio; Riccio Ed; Doppalapudi Rupa; Kapetanovic Izet M; Steward William P; Gescher Andreas J
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone.
Cancer chemotherapy and pharmacology 2006;57(1):1-6.
-
2005: Zongaro Samantha; de Stanchina Elisa; Colombo Tina; D'Incalci Maurizio; Giulotto Elena; Mondello Chiara
Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
Cancer research 2005;65(24):11411-8.
-
2005: Manara M C; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger C M; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
International journal of oncology 2005;27(6):1605-16.
-
2005: Tognon Gianluca; Bernasconi Sergio; Celli Nicola; Faircloth Glynn T; Cuevas Carmen; Jimeno José; Erba Eugenio; D'Incalci Maurizio
Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
Cancer biology & therapy 2005;4(12):1325-30.
-
2005: D'Incalci Maurizio; Steward William P; Gescher Andreas J
Use of cancer chemopreventive phytochemicals as antineoplastic agents.
The lancet oncology 2005;6(11):899-904.
-
2005: Minuzzo Mario; Ceribelli Michele; Pitarque-Martì Marià; Borrelli Serena; Erba Eugenio; DiSilvio Alberto; D'Incalci Maurizio; Mantovani Roberto
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters.
Molecular pharmacology 2005;68(5):1496-503.
-
2005: Simone Matteo; Erba Eugenio; Damia Giovanna; Vikhanskaya Faina; Di Francesco Angela M; Riccardi Riccardo; Bailly Christian; Cuevas Carmen; Fernandez Sousa-Faro José Maria; D'Incalci Maurizio
Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2366-77.
-
2005: Di Francesco Angela Maria; Riccardi Anna; Barone Giuseppe; Rutella Sergio; Meco Daniela; Frapolli Roberta; Zucchetti Massimo; D'Incalci Maurizio; Pisano Claudio; Carminati Paolo; Riccardi Riccardo
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Biochemical pharmacology 2005;70(8):1125-36.
-
2005: Riccardi Anna; Meco Daniela; Ubezio Paolo; Mazzarella Giorgio; Marabese Mirko; Faircloth Glynn T; Jimeno José; D'Incalci Maurizio; Riccardi Riccardo
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Anti-cancer drugs 2005;16(8):811-5.
-
2005: D'Incalci Maurizio; Zupi Gabriella
Are we close to the clinical development of novel drugs targeting telomeres and telomerase?
European journal of cancer (Oxford, England : 1990) 2005;41(7):970.
-
2005: Allavena Paola; Signorelli Mauro; Chieppa Marcello; Erba Eugenio; Bianchi Giancarlo; Marchesi Federica; Olimpio Chiara Omero; Bonardi Claudia; Garbi Annalisa; Lissoni Andrea; de Braud Filippo; Jimeno José; D'Incalci Maurizio
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Cancer research 2005;65(7):2964-71.
-
2005: Sessa Cristiana; De Braud Filippo; Perotti Antonella; Bauer Jean; Curigliano Giuseppe; Noberasco Cristina; Zanaboni Flavia; Gianni Luca; Marsoni Silvia; Jimeno José; D'Incalci Maurizio; Dall'ó Elisa; Colombo Nicoletta
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1867-74.
-
2005: Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek F J; Broggini M; Faircloth G T; D'Incalci M
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
European journal of cancer (Oxford, England : 1990) 2005;41(2):323-33.
-
2004: D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
New drugs from the sea.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():86-9.
-
2004: Leonetti Carlo; Amodei Sarah; D'Angelo Carmen; Rizzo Angela; Benassi Barbara; Antonelli Anna; Elli Raffaella; Stevens Malcolm F G; D'Incalci Maurizio; Zupi Gabriella; Biroccio Annamaria
Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration.
Molecular pharmacology 2004;66(5):1138-46.
-
2004: Donald Sarah; Verschoyle Richard D; Greaves Peter; Colombo Tina; Zucchetti Massimo; Falcioni Cristiano; Zaffaroni Marco; D'Incalci Maurizio; Manson Margaret M; Jimeno Jose; Steward William P; Gescher Andreas J
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
International journal of cancer. Journal international du cancer 2004;111(6):961-7.
-
2004: Taraboletti G; Poli M; Dossi R; Manenti L; Borsotti P; Faircloth G T; Broggini M; D'Incalci M; Ribatti D; Giavazzi R
Antiangiogenic activity of aplidine, a new agent of marine origin.
British journal of cancer 2004;90(12):2418-24.
-
2004: Lupi Monica; Matera Giada; Branduardi Davide; D'Incalci Maurizio; Ubezio Paolo
Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.
Cancer research 2004;64(8):2825-32.
-
2004: Celli Nicola; Mariani Barbara; Di Carlo Francesco; Zucchetti Massimo; Lopez-Lazaro Luis; D'Incalci Maurizio; Rotilio Domenico
Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection.
Journal of pharmaceutical and biomedical analysis 2004;34(3):619-30.
-
2004: Tognon Gianluca; Frapolli Roberta; Zaffaroni Marco; Erba Eugenio; Zucchetti Massimo; Faircloth Glynn T; D'Incalci Maurizio
Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Cancer chemotherapy and pharmacology 2004;53(1):89-90.
-
2004: Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco A M; Riccardi R; Cuevas C; Faircloth G T; D'Incalci M
The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Oncology research 2004;14(11-12):579-87.
-
2003: D'Incalci Maurizio; Jimeno José
Preclinical and clinical results with the natural marine product ET-743.
Expert opinion on investigational drugs 2003;12(11):1843-53.
-
2003: Zaffaroni M; Mucignat C; Pecere T; Zagotto G; Frapolli R; D'Incalci M; Zucchetti M
High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):113-9.
-
2003: Donald Sarah; Verschoyle Richard D; Greaves Peter; Gant Timothy W; Colombo Tina; Zaffaroni Marco; Frapolli Roberta; Zucchetti Massimo; D'Incalci Maurizio; Meco Daniela; Riccardi Riccardo; Lopez-Lazaro Luis; Jimeno Jose; Gescher Andreas J
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Cancer research 2003;63(18):5902-8.
-
2003: D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth G T
The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1920-6.
-
2003: Gambacorti-Passerini Carlo; Piazza Rocco; D'Incalci Maurizio
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.
Blood 2003;102(5):1933-4; author reply 1934-5.
-
2003: Mondello Chiara; Chiesa Massimo; Rebuzzini Paola; Zongaro Samantha; Verri Annalisa; Colombo Tina; Giulotto Elena; D'Incalci Maurizio; Franceschi Claudio; Nuzzo Fiorella
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals.
Biochemical and biophysical research communications 2003;308(4):914-21.
-
2003: Erba E; Serafini M; Gaipa G; Tognon G; Marchini S; Celli N; Rotilio D; Broggini M; Jimeno J; Faircloth G T; Biondi A; D'Incalci M
Effect of Aplidin in acute lymphoblastic leukaemia cells.
British journal of cancer 2003;89(4):763-73.
-
2003: Meco Daniela; Colombo Tina; Ubezio Paolo; Zucchetti Massimo; Zaffaroni Marco; Riccardi Anna; Faircloth Glynn; Jose Jimeno; D'Incalci Maurizio; Riccardi Riccardo
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Cancer chemotherapy and pharmacology 2003;52(2):131-8.
-
2003: Pratesi G; Laccabue D; Lanzi C; Cassinelli G; Supino R; Zucchetti M; Frapolli R; D'Incalci M; Bombardelli E; Morazzoni P; Riva A; Zunino F
IDN 5390: an oral taxane candidate for protracted treatment schedules.
British journal of cancer 2003;88(6):965-72.
-
2003: Biroccio Annamaria; Gabellini Chiara; Amodei Sarah; Benassi Barbara; Del Bufalo Donatella; Elli Raffaella; Antonelli Anna; D'Incalci Maurizio; Zupi Gabriella
Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.
Molecular pharmacology 2003;63(3):632-8.
-
2003: Gambacorti-Passerini Carlo; Zucchetti Massimo; Russo Domenico; Frapolli Roberta; Verga Magda; Bungaro Silvia; Tornaghi Lucia; Rossi Fabio; Pioltelli Pietro; Pogliani Enrico; Alberti Daniele; Corneo Gianmarco; D'Incalci Maurizio
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):625-32.
-
2003: Broggini M; Marchini S V; Galliera E; Borsotti P; Taraboletti G; Erba E; Sironi M; Jimeno J; Faircloth G T; Giavazzi R; D'Incalci M
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):52-9.
-
2002: Scotlandi Katia; Perdichizzi Stefania; Manara Maria Cristina; Serra Massimo; Benini Stefania; Cerisano Vanessa; Strammiello Rosaria; Mercuri Mario; Reverter-Branchat Gemma; Faircloth Glynn; D'Incalci Maurizio; Picci Piero
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3893-903.
-
2002: Zaffaroni M; Frapolli R; Colombo T; Fruscio R; Bombardelli E; Morazzoni P; Riva A; D'Incalci M; Zucchetti M
High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;780(1):93-8.
-
2002: D'Incalci Maurizio
Professor Maurizio D'Incalci interviewed by Emma Cannell.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1559.
-
2002: Marchini S; Chiorino G; Faircloth G T; D'Incalci M
Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines.
Journal of biological regulators and homeostatic agents 2002;16(3):241-8.
-
2002: Rizzi Massimo; Caccia Silvio; Guiso Giovanna; Richichi Cristina; Gorter Jan A; Aronica Eleonora; Aliprandi Marisa; Bagnati Renzo; Fanelli Roberto; D'Incalci Maurizio; Samanin Rosario; Vezzani Annamaria
Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(14):5833-9.
-
2002: Gambacorti-Passerini Carlo; le Coutre Philipp; Zucchetti Massimo; D'Incalci Maurizio
Binding of imatinib by alpha(1)-acid glycoprotein.
Blood 2002;100(1):367-8; author reply 368-9.
-
2002: D'Incalci Maurizio
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1297.
-
2002: Gambacorti-Passerini Carlo B; Rossi Francesca; Verga Magda; Ruchatz Holger; Gunby Rosalind; Frapolli Roberta; Zucchetti Massimo; Scapozza Leonardo; Bungaro Silvia; Tornaghi Lucia; Rossi Fabio; Pioltelli Pietro; Pogliani Enrico; D'Incalci Maurizio; Corneo Gianmarco
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.
Blood cells, molecules & diseases 2002;28(3):361-72.
-
2002: Erba E; Bassano L; Di Liberti G; Muradore I; Chiorino G; Ubezio P; Vignati S; Codegoni A; Desiderio M A; Faircloth G; Jimeno J; D'Incalci M
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.
British journal of cancer 2002;86(9):1510-7.
-
2002: Geroni Cristina; Marchini Sergio; Cozzi Paolo; Galliera Emanuela; Ragg Enzio; Colombo Tina; Battaglia Rosangela; Howard Martin; D'Incalci Maurizio; Broggini Massimo
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Cancer research 2002;62(8):2332-6.
-
2002: D'Incalci Maurizio; Erba Eugenio; Damia Giovanna; Galliera Emanuela; Carrassa Laura; Marchini Sergio; Mantovani Roberto; Tognon Gianluca; Fruscio Robert; Jimeno José; Faircloth Glynn T
Unique features of the mode of action of ET-743.
The oncologist 2002;7(3):210-6.
-
2001: Laccabue D; Tortoreto M; Veneroni S; Perego P; Scanziani E; Zucchetti M; Zaffaroni M; D'Incalci M; Bombardelli E; Zunino F; Pratesi G
A novel taxane active against an orthotopically growing human glioma xenograft.
Cancer 2001;92(12):3085-92.
-
2001: Marchini S; Broggini M; Sessa C; D'Incalci M
Development of distamycin-related DNA binding anticancer drugs.
Expert opinion on investigational drugs 2001;10(9):1703-14.
-
2001: Cappella P; Tomasoni D; Faretta M; Lupi M; Montalenti F; Viale F; Banzato F; D'Incalci M; Ubezio P
Cell cycle effects of gemcitabine.
International journal of cancer. Journal international du cancer 2001;93(3):401-8.
-
2001: Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth G T; Liberi G; Foiani M; D'Incalci M
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
International journal of cancer. Journal international du cancer 2001;92(4):583-8.
-
2001: Damia G; Filiberti L; Vikhanskaya F; Carrassa L; Taya Y; D'incalci M; Broggini M
Cisplatinum and taxol induce different patterns of p53 phosphorylation.
Neoplasia (New York, N.Y.) 2001;3(1):10-6.
-
2001: Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth G T; D'Incalci M
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
European journal of cancer (Oxford, England : 1990) 2001;37(1):97-105.
-
2001: Sottani C; Colombo T; Zucchetti M; Fruscio R; D'Incalci M; Minoia C
High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples.
Rapid communications in mass spectrometry : RCM 2001;15(19):1807-16.
-
2000: Broggini M; Buraggi G; Brenna A; Riva L; Codegoni A M; Torri V; Lissoni A A; Mangioni C; D'Incalci M
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.
Anticancer research 2000;20(6C):4835-40.
-
2000: Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Journal of the National Cancer Institute 2000;92(20):1641-50.
-
2000: Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):985-91.
-
2000: Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(12):6780-4.
-
2000: De Feudis P; Vignati S; Rossi C; Mincioni T; Giavazzi R; D'Incalci M; Broggini M
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.
Neoplasia (New York, N.Y.) 2000;2(3):202-7.
-
2000: Conforti G; Nardo T; D'Incalci M; Stefanini M
Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation.
Oncogene 2000;19(22):2714-20.
-
2000: Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
British journal of cancer 2000;82(10):1732-9.
-
2000: Polizzi D; Pratesi G; Monestiroli S; Tortoreto M; Zunino F; Bombardelli E; Riva A; Morazzoni P; Colombo T; D'Incalci M; Zucchetti M
Oral efficacy and bioavailability of a novel taxane.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):2070-4.
-
2000: Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):189-93.
-
2000: Nicoletti M I; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati M B; Bombardelli E; D'Incalci M; Giavazzi R
IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Cancer research 2000;60(4):842-6.
-
2000: Vikhanskaya F; D'Incalci M; Broggini M
p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Nucleic acids research 2000;28(2):513-9.
-
2000: Fumagalli L; Zucchetti M; Parisi I; Viganò M G; Zecca B; Careddu A; D'Incalci M; Lazzarin A
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Cancer chemotherapy and pharmacology 2000;45(6):495-501.
-
1999: Colombo T; Frapolli R; Bombardelli E; Morazzoni P; Riva A; D'Incalci M; Zucchetti M
High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):135-41.
-
1999: Celli N; Gallardo A M; Rossi C; Zucchetti M; D'Incalci M; Rotilio D
Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 1999;731(2):335-43.
-
1999: Codegoni A M; Bertoni F; Patregnani C; Marinetti E; D'Incalci M; Broggini M
Allelic expression of p73 in human ovarian cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):949-53.
-
1999: Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(7):831-8.
-
1999: Bonfanti M; La Valle E; Fernandez Sousa Faro J M; Faircloth G; Caretti G; Mantovani R; D'Incalci M
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
Anti-cancer drug design 1999;14(3):179-86.
-
1999: Marchini S; Cirò M; Gallinari F; Geroni C; Cozzi P; D'Incalci M; Broggini M
Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
British journal of cancer 1999;80(7):991-7.
-
1999: Erba E; Bergamaschi D; Ronzoni S; Faretta M; Taverna S; Bonfanti M; Catapano C V; Faircloth G; Jimeno J; D'Incalci M
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity.
British journal of cancer 1999;80(7):971-80.
-
1999: Erba E; Ronzoni S; Bassano L; Giavazzi R; D'Incalci M
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):589-91.
-
1999: Colella G; Marchini S; D'Incalci M; Brown R; Broggini M
Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.
British journal of cancer 1999;80(3-4):338-43.
-
1999: Colombo T; Parisi I; Zucchetti M; Sessa C; Goldhirsch A; D'Incalci M
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):391-5.
-
1999: Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):937-41.
-
1999: Bergamaschi D; Ronzoni S; Taverna S; Faretta M; De Feudis P; Faircloth G; Jimeno J; Erba E; D'Incalci M
Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound.
British journal of cancer 1999;79(2):267-77.
-
1999: Codegoni A M; Bertoni F; Colella G; Caspani G; Grassi L; D'Incalci M; Broggini M
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.
Oncology research 1999;11(7):297-301.
-
1999: Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini M A; Domenigoni L; Cavalli F
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Cancer chemotherapy and pharmacology 1999;44(5):403-10.
-
1999: Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Cancer chemotherapy and pharmacology 1999;44(2):173-6.
-
1998: D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Seminars in oncology 1998;25(6 Suppl 13):16-20.
-
1998: Damia G; Guidi G; D'Incalci M
Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1783-8.
-
1998: D'Incalci M; Bonfanti M; Pifferi A; Mascellani E; Tagliabue G; Berger D; Fiebig H H
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1749-55.
-
1998: Codegoni A M; Nicoletti M I; Buraggi G; Valoti G; Giavazzi R; D'Incalci M; Landoni F; Maneo A; Broggini M
Molecular characterisation of a panel of human ovarian carcinoma xenografts.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1432-8.
-
1998: Valoti G; Nicoletti M I; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1977-83.
-
1998: Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Experimental cell research 1998;241(1):96-101.
-
1998: Colella G; Vikhanskaya F; Codegoni A M; Bonazzi C; D'Incalci M; Broggini M
hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors.
Carcinogenesis 1998;19(4):691-4.
-
1998: Marchini S; Cozzi P; Beria I; Geroni C; Capolongo L; D'Incalci M; Broggini M
Sequence-specific DNA alkylation of novel tallimustine derivatives.
Anti-cancer drug design 1998;13(3):193-205.
-
1998: Codegoni A M; Castagna S; Mangioni C; Scovassi A I; Broggini M; D'Incalci M
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):313-9.
-
1998: Donelli M G; Zucchetti M; Munzone E; D'Incalci M; Crosignani A
Pharmacokinetics of anticancer agents in patients with impaired liver function.
European journal of cancer (Oxford, England : 1990) 1998;34(1):33-46.
-
1998: Sottani C; Minoia C; D'Incalci M; Paganini M; Zucchetti M
High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma.
Rapid communications in mass spectrometry : RCM 1998;12(5):251-5.
-
1997: Filippini C; Bisiach M; Tagliabue G; D'Incalci M; Ubezio P
Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents.
International journal of cancer. Journal international du cancer 1997;72(5):801-9.
-
1997: D'Incalci M; Sessa C
DNA minor groove binding ligands: a new class of anticancer agents.
Expert opinion on investigational drugs 1997;6(7):875-84.
-
1997: Bonfanti M; Colella G; Broggini M; D'Incalci M
Effect of G:C-->A:T transition, potentially arising from O6-guanine alkylation, in the transcription regulation of c-fos serum response element.
Anticancer research 1997;17(3C):2019-24.
-
1997: Bonfanti M; Taverna S; Salmona M; D'Incalci M; Broggini M
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
Cancer research 1997;57(8):1442-6.
-
1997: Codegoni A M; Broggini M; Pitelli M R; Pantarotto M; Torri V; Mangioni C; D'Incalci M
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Gynecologic oncology 1997;65(1):130-7.
-
1997: Debernardis D; Siré E G; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Cancer research 1997;57(5):870-4.
-
1997: Tagliabue G; Filippini C; Ubezio P; D'Incalci M
Combination of the new minor groove alkylator tallimustine and melphalan.
European journal of cancer (Oxford, England : 1990) 1997;33(2):284-7.
-
1997: Faretta M; Bergamaschi D; Ronzoni S; D'Incalci M; Erba E
Differences in cyclin B1 expression in cells blocked in the G2M phase after treatment with anticancer agent. New three-parametric flow cytometric analysis.
European journal of histochemistry : EJH 1997;41 Suppl 2():73-4.
-
1997: Bergamaschi D; Faretta M; Ronzoni S; Taverna S; De Feudis P; Bonfanti M; Guidi G; Faircloth M; Jimeno J; D'Incalci M; Erba E
Flow cytometric analysis of cell cycle phase perturbations induced by Thiocoraline, a new marine-derived anticancer compound.
European journal of histochemistry : EJH 1997;41 Suppl 2():63-4.
-
1997: Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
DNA topoisomerase II poisons and inhibitors.
Cancer chemotherapy and biological response modifiers 1997;17():114-31.
-
1997: De Feudis P; Debernardis D; Beccaglia P; Valenti M; Graniela Siré E; Arzani D; Stanzione S; Parodi S; D'Incalci M; Russo P; Broggini M
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
British journal of cancer 1997;76(4):474-9.
-
1997: Sottani C; Minoia C; Colombo A; Zucchetti M; D'Incalci M; Fanelli R
Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 1997;11(9):1025-32.
-
1997: Desiderio M A; Bergamaschi D; Mascellani E; De Feudis P; Erba E; D'Incalci M
Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
British journal of cancer 1997;75(7):1028-34.
-
1996: Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries E G; D'Incalci M
In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2011-8.
-
1996: Colombo T; Gonzalez Paz O; Zucchetti M; Maneo A; Sessa C; Goldhirsch A; D'Incalci M;
Paclitaxel induces significant changes in epidoxorubicin distribution in mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):801-5.
-
1996: Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(7):725-30.
-
1996: Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Experimental cell research 1996;227(2):380-5.
-
1996: Codegoni A M; Landoni F; Lomonico S; Losa G; Mangioni C; Taverna M; Lucchini V; D'Incalci M
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma.
Cancer 1996;78(3):448-53.
-
1996: Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1123-7.
-
1996: Damia G; Imperatori L; Stefanini M; D'Incalci M
Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
International journal of cancer. Journal international du cancer 1996;66(6):779-83.
-
1996: Colombo T; Gonzalez Paz O; D'Incalci M
Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
British journal of cancer 1996;73(7):866-71.
-
1996: Damia G; Imperatori L; Citti L; Mariani L; D'Incalci M
3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines.
British journal of cancer 1996;73(7):861-5.
-
1996: Popolo L; Viganò F; Erba E; Mongelli N; D'Incalci M
Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle.
Yeast (Chichester, England) 1996;12(4):349-59.
-
1996: Pagani O; Zucchetti M; Sessa C; de Jong J; D'Incalci M; De Fusco M; Kaeser-Fröhlich A; Hanauske A; Cavalli F
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Cancer chemotherapy and pharmacology 1996;38(6):541-7.
-
1995: Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1517-24.
-
1995: Marchini S; Gonzalez Paz O; Ripamonti M; Geroni C; Bargiotti A; Caruso M; Todeschi S; D'Incalci M; Broggini M
Sequence-specific DNA interactions by novel alkylating anthracycline derivatives.
Anti-cancer drug design 1995;10(8):641-53.
-
1995: Erba E; Mascellani E; Pifferi A; D'Incalci M
Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line.
International journal of cancer. Journal international du cancer 1995;62(2):170-5.
-
1995: Damia G; D'Incalci M
Clinical pharmacokinetics of altretamine.
Clinical pharmacokinetics 1995;28(6):439-48.
-
1995: Bellorini M; Moncollin V; D'Incalci M; Mongelli N; Mantovani R
Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription.
Nucleic acids research 1995;23(10):1657-63.
-
1995: Vikhanskaya F; D'Incalci M; Broggini M
Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes.
International journal of cancer. Journal international du cancer 1995;61(3):397-401.
-
1995: Donelli M G; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi M R
Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
Medical and pediatric oncology 1995;24(3):154-9.
-
1995: Cattabeni M; D'Incalci M; Broggini M
Differential expression of c-fos proto-oncogene in two subclones derived from a human ovarian cancer cell line.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(2):255-63.
-
1995: De Fusco M; D'Incalci M; Gentili D; Reichert S; Zucchetti M
High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients.
Journal of chromatography. B, Biomedical applications 1995;664(2):409-14.
-
1995: Broggini M; Coley H M; Mongelli N; Pesenti E; Wyatt M D; Hartley J A; D'Incalci M
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.
Nucleic acids research 1995;23(1):81-7.
-
1995: Gonzalez O; Colombo T; De Fusco M; Imperatori L; Zucchetti M; D'Incalci M
Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.
Cancer chemotherapy and pharmacology 1995;36(4):335-40.
-
1994: Diomede L; Damia G; D'Incalci M; Imperatori L; Algeri M; Modest E J; Salmona M
In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition.
International journal of cancer. Journal international du cancer 1994;59(4):580-1.
-
1994: Bonfanti M; Taverna P; Mangioni C; Losa G; Taverna M; D'Incalci M
Interferon-beta does not change the level of O6-alkylguanine-DNA alkyltransferase in cancer patients' lymphocytes.
Anti-cancer drugs 1994;5(5):601-2.
-
1994: Broggini M; D'Incalci M
Modulation of transcription factor--DNA interactions by anticancer drugs.
Anti-cancer drug design 1994;9(4):373-87.
-
1994: Gentili D; Zucchetti M; Conter V; Masera G; D'Incalci M
Determination of L-asparagine in biological samples in the presence of L-asparaginase.
Journal of chromatography. B, Biomedical applications 1994;657(1):47-52.
-
1994: Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53.
Nucleic acids research 1994;22(6):1012-7.
-
1994: Imperatori L; Damia G; Taverna P; Garattini E; Citti L; Boldrini L; D'Incalci M
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
Carcinogenesis 1994;15(3):533-7.
-
1994: Zucchetti M; De Fusco M; Sessa C; Fröhlich A; Reichert S; D'Incalci M
High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma.
Journal of chromatography. B, Biomedical applications 1994;654(1):97-102.
-
1994: Geroni C; Pesenti E; Broggini M; Belvedere G; Tagliabue G; D'Incalci M; Pennella G; Grandi M
L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
British journal of cancer 1994;69(2):315-9.
-
1994: Erba E; Sen S; Sessa C; Vikhanskaya F L; D'Incalci M
Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
British journal of cancer 1994;69(2):205-11.
-
1994: Sen S; Zocchetti A; Beccaglia P; Balconi G; Erba E; D'Incalci M
Heterogeneous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):892-3.
-
1994: Nicoletti M I; Lucchini V; D'Incalci M; Giavazzi R
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):691-6.
-
1993: Vikhanskaya F; D'Incalci M; Broggini M
Effects of DNA damaging agents on gene expression in two human cancer cell lines.
Cellular and molecular biology (Noisy-le-Grand, France) 1993;39(8):855-62.
-
1993: D'Incalci M
DNA-topoisomerase inhibitors.
Current opinion in oncology 1993;5(6):1023-8.
-
1993: Fabbri S; Prontera C; Broggini M; D'Incalci M
Differential inhibition of the DNA binding of transcription factors NF kappa B and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications.
Carcinogenesis 1993;14(9):1963-7.
-
1993: Sessa C; Zucchetti M; Torri V; Pagani O; D'Incalci M; Gentili D; Martinelli G; deJong J; Alerci M; Cavalli F
Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):553-8.
-
1993: Balconi G; Damia G; Morali F; Marzola M; Tagliabue G; Erba E; D'Incalci M
Cis-diamminedichloroplatinum sensitivity of murine reticulum sarcoma cells in primary culture and after in vitro passages.
In vitro cellular & developmental biology. Animal 1993;29A(8):617-9.
-
1993: Marzola M; Zucchetti M; Colombo N; Sessa C; Pagani O; D'Incalci M; Cavalli F; Mangioni C
Low-dose oral etoposide in epithelial cancer of the ovary.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(6):517-9.
-
1993: Davoli E; Zucchetti M; D'Incalci M; Sessa C; Cavalli F; Fanelli R
Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients.
Biological mass spectrometry 1993;22(6):351-7.
-
1993: Tagliabue G; Pifferi A; Balconi G; Mascellani E; Geroni C; D'Incalci M; Ubezio P
Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents.
International journal of cancer. Journal international du cancer 1993;54(3):435-42.
-
1993: Lee M; Rhodes A L; Wyatt M D; D'Incalci M; Forrow S; Hartley J A
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
Journal of medicinal chemistry 1993;36(7):863-70.
-
1993: Coley H M; Mongelli N; D'Incalci M
The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
Biochemical pharmacology 1993;45(3):619-26.
-
1993: Nicoletti M I; Lucchini V; Massazza G; Abbott B J; D'Incalci M; Giavazzi R
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(2):151-5.
-
1993: Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
International journal of cancer. Journal international du cancer 1993;53(2):308-14.
-
1993: D'Incalci M; Capranico G; Giaccone G; Zunino F; Garattini S
DNA topoisomerase inhibitors.
Cancer chemotherapy and biological response modifiers 1993;14():61-85.
-
1993: Gentili D; Zucchetti M; Torri V; Sessa C; de Jong J; Cavalli F; D'Incalci M
A limited sampling model for the pharmacokinetics of etoposide given orally.
Cancer chemotherapy and pharmacology 1993;32(6):482-6.
-
1992: Tagliabue G; Citti L; Massazza G; Damia G; Giavazzi R; D'Incalci M
Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts.
Anticancer research 1992;12(6B):2123-5.
-
1992: Pardini C; Piras A; Voliani M; Rainaldi G; Mariani L; Taverna P; D'Incalci M; Citti L
Chinese hamster ovary cells deficient or proficient in O6-alkylguanine-DNA alkyltransferase activity are equally sensitive to X-rays.
Mutation research 1992;283(2):125-9.
-
1992: Taverna P; Catapano C V; Citti L; Bonfanti M; D'Incalci M
Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas.
Anti-cancer drugs 1992;3(4):401-5.
-
1992: Coccia P; Bertini R; Pagani P; Marinello C; Taverna P; Villa P; D'Incalci M
O6-alkylguanine DNA alkyltransferase is induced by human recombinant interferon-alpha A/D in mouse liver.
Journal of interferon research 1992;12(3):173-6.
-
1992: Taverna P; Garattini E; Citti L; Damia G; D'Incalci M
Expression of E. coli tag gene encoding 3-methyladenine glycosylase I in NIH-3T3 murine fibroblasts.
Biochemical and biophysical research communications 1992;185(1):41-6.
-
1992: Donelli M G; Zucchetti M; D'Incalci M
Do anticancer agents reach the tumor target in the human brain?
Cancer chemotherapy and pharmacology 1992;30(4):251-60.
-
1992: Coccia P; Sen S; Erba E; Pagani P; Marinello C; D'Incalci M
O6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells.
Cancer chemotherapy and pharmacology 1992;30(1):77-80.
-
1992: Bonfanti M; Taverna P; Chiappetta L; Villa P; D'Incalci M; Bagnati R; Fanelli R
DNA damage induced by alachlor after in vitro activation by rat hepatocytes.
Toxicology 1992;72(2):207-19.
-
1992: Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Cancer chemotherapy and pharmacology 1992;30(6):459-64.
-
1992: Erba E; Sen S; Lorico A; D'Incalci M
Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin.
European journal of cancer (Oxford, England : 1990) 1992;28(1):66-71.
-
1991: Bonfanti M; Broggini M; Prontera C; D'Incalci M
O6-methylguanine inhibits the binding of transcription factors to DNA.
Nucleic acids research 1991;19(20):5739-42.
-
1991: D'Incalci M; Broxterman H J; van Kalken C K
AACR special conference in cancer research. Membrane transport in multidrug resistance, development, and disease. American Association for Cancer Research.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(9):635-9.
-
1991: Sessa C; Zucchetti M; Davoli E; Califano R; Cavalli F; Frustaci S; Gumbrell L; Sulkes A; Winograd B; D'Incalci M
Phase I and clinical pharmacological evaluation of aphidicolin glycinate.
Journal of the National Cancer Institute 1991;83(16):1160-4.
-
1991: Ponti M; Forrow S M; Souhami R L; D'Incalci M; Hartley J A
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase.
Nucleic acids research 1991;19(11):2929-33.
-
1991: Galligioni E; Quaia M; Spada A; Crivellari D; Favaro D; Sorio R; Talamini R; D'Incalci M; Allavena P; Damia G
Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(2):145-50.
-
1991: D'Incalci M; Taverna P; Erba E; Filippeschi S; Potenza D; Mariani L; Citti L; Catapano C V
O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia.
Anticancer research 1991;11(1):115-21.
-
1991: Zucchetti M; Rossi C; Knerich R; Donelli M G; Butti G; Silvani V; Gaetani P; D'Incalci M
Concentrations of VP16 and VM26 in human brain tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(1):63-6.
-
1991: Broggini M; Erba E; Ponti M; Ballinari D; Geroni C; Spreafico F; D'Incalci M
Selective DNA interaction of the novel distamycin derivative FCE 24517.
Cancer research 1991;51(1):199-204.
-
1990: Damia G; Garofalo A; Rossi C; Giavazzi R; D'Incalci M
Flavone acetic acid pharmacokinetics in nude mice.
Anticancer research 1990;10(2A):437-9.
-
1990: Laudonio N; Zupi G; Erba E; Leonetti C; D'Incalci M
Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
British journal of cancer 1990;61(3):377-81.
-
1990: Broggini M; Hartley J A; Mattes W B; Ponti M; Kohn K W; D'Incalci M
DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)
British journal of cancer 1990;61(2):285-9.
-
1990: Bertini R; Coccia P; Pagani P; Marinello C; Salmona M; D'Incalci M
Interferon inducers increase O6-alkylguanine-DNA alkyltransferase in the rat liver.
Carcinogenesis 1990;11(1):181-3.
-
1990: Allavena P; Pirovano P; Bonazzi C; Colombo N; Mantovani A; D'Incalci M
In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells.
Journal of the National Cancer Institute 1990;82(2):139-42.
-
1990: Sen S; Erba E; D'Incalci M
Synchronisation of cancer cell lines of human origin using methotrexate.
Cytometry 1990;11(5):595-602.
-
1990: Damia G; Freschi A; Sorio R; Braida A; Caruso G; Quaia M; Monfardini S; D'Incalci M
Flavone acetic acid distribution in human malignant tumors.
Cancer chemotherapy and pharmacology 1990;26(1):67-70.
-
1990: Zanette L; Zucchetti M; Freshi A; Erranti D; Tirelli U; D'Incalci M
Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
Cancer chemotherapy and pharmacology 1990;25(6):445-8.
-
1990: Capolongo L; Belvedere G; D'Incalci M
DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.
Cancer chemotherapy and pharmacology 1990;25(6):430-4.
-
1990: Montaldo P G; Figoli F; Zanette M L; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Oncology 1990;47(1):55-61.
-
1990: Damia G; Tagliabue G; Allavena P; D'Incalci M
Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.
Cancer immunology, immunotherapy : CII 1990;32(4):241-4.
-
1990: Limonta M; Biondi A; Giudici G; Specchia G; Catapano C; Masera G; Barbui T; D'Incalci M
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Cancer chemotherapy and pharmacology 1990;26(5):340-2.
-
1989: Ubezio P; Limonta M; D'Incalci M; Damia G; Masera G; Giudici G; Wolverton J S; Beck W T
Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.
European journal of cancer & clinical oncology 1989;25(12):1895-9.
-
1989: Belvedere G; Suarato A; Geroni C; Giuliani F C; D'Incalci M
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).
Biochemical pharmacology 1989;38(21):3713-21.
-
1989: Massazza G; Tomasoni A; Lucchini V; Allavena P; Erba E; Colombo N; Mantovani A; D'Incalci M; Mangioni C; Giavazzi R
Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.
International journal of cancer. Journal international du cancer 1989;44(3):494-500.
-
1989: Erba E; Ubezio P; Pepe S; Vaghi M; Marsoni S; Torri W; Mangioni C; Landoni F; D'Incalci M
Flow cytometric analysis of DNA content in human ovarian cancers.
British journal of cancer 1989;60(1):45-50.
-
1989: Zucchetti M; Catapano C V; Filippeschi S; Erba E; D'Incalci M
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
Biochemical pharmacology 1989;38(13):2069-75.
-
1989: Montaldo P G; D'Incalci M
High-performance liquid chromatographic determination of 5-bromodeoxyuridine in human plasma.
Journal of chromatography 1989;491(1):129-38.
-
1989: Ferrari A; Damia G; Erba E; Rossi C; Mandelli R; D'Incalci M
Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
International journal of cancer. Journal international du cancer 1989;43(6):1091-7.
-
1989: Rotondo S; Zucchetti M; Sessa C; D'Incalci M; Benfenati E; Fanelli R
A gas chromatographic mass spectrometric assay for the determination of aphidicolin in plasma of cancer patients.
Journal of pharmaceutical sciences 1989;78(5):399-401.
-
1989: Benfenati E; Zucchetti M; D'Incalci M
Identification of microsomal metabolites of spirogermanium.
Anticancer research 1989;9(2):507-10.
-
1989: Broggini M; Ponti M; Ottolenghi S; D'Incalci M; Mongelli N; Mantovani R
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.
Nucleic acids research 1989;17(3):1051-9.
-
1989: D'Incalci M; Balconi G; Broggini M; Colombo T; Marzola M; Morali F; Pang Y; Sen S; Spinelli L
Problems in the design of anticancer agents.
Cancer surveys 1989;8(3):535-55.
-
1989: Benfenati E; Farina P; Colombo T; De Bellis G; Capodiferro M V; D'Incalci M
Metabolism and pharmacokinetics of p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice.
Cancer chemotherapy and pharmacology 1989;24(6):354-8.
-
1989: Mannironi C; Erba E; Corda D; Gianellini L; D'Incalci M
Changes in the synthesis of histone H1(0) and H1 in rat FRTL-5 thyroid cells exposed to thyrotropin.
Life sciences 1989;45(23):2209-16.
-
1988: Broggini M; Grandi M; Ubezio P; Geroni C; Giuliani F C; D'Incalci M
Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.
Biochemical pharmacology 1988;37(23):4423-31.
-
1988: D'Incalci M; Citti L; Taverna P; Catapano C V
Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy.
Cancer treatment reviews 1988;15(4):279-92.
-
1988: Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A
Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
Anticancer research 1988;8(6):1351-4.
-
1988: Mannironi C; D'Incalci M
Doxorubicin induces the acetylation of histone H1 in a human colon cancer cell line (LoVo/DX) selected for resistance to the drug, but not in the sensitive parental line (LoVo).
Biochemical and biophysical research communications 1988;155(3):1221-9.
-
1988: Mannironi C; Rossi V; Biondi A; Ubezio P; Giudici G; Masera G; D'Incalci M
Comparison of histone variant synthesis in human lymphocytic leukemia cells and in normal lymphocytes.
Cancer research 1988;48(13):3670-5.
-
1988: Balconi G; Broggini M; Erba E; D'Incalci M; Colombo N; Mangioni C; Bertolero F
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro.
International journal of cancer. Journal international du cancer 1988;41(6):809-18.
-
1988: Catapano C V; Ubezio P; Rossi V; Conter V; Jancovich M; D'Incalci M
Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin.
Biochemical pharmacology 1988;37(9):1863-4.
-
1988: Broggini M; Balconi G; Bertolero F; Erba E; Landoni F; Mangioni C; D'Incalci M
DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture.
Biochemical pharmacology 1988;37(9):1835-6.
-
1988: Sessa C; Zucchetti M; Ginier M; Willems Y; D'Incalci M; Cavalli F
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.
European journal of cancer & clinical oncology 1988;24(4):769-75.
-
1988: Giavazzi R; Garofalo A; Damia G; Garattini S; D'Incalci M
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
British journal of cancer 1988;57(3):277-80.
-
1988: Erba E; Ubezio P; Broggini M; Ponti M; D'Incalci M
DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro.
Cytometry 1988;9(1):1-6.
-
1988: Zucchetti M; D'Incalci M; Willems Y; Cavalli F; Sessa C
Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.
Cancer chemotherapy and pharmacology 1988;22(1):87-9.
-
1988: Damia G; Zanette M L; Rossi C; Mandelli R; Ferrari A; D'Incalci M
Dose-dependent pharmacokinetics of flavone acetic acid in mice.
Cancer chemotherapy and pharmacology 1988;22(1):47-50.
-
1987: Rossi C; Gasparini G; Canobbio L; Galligioni E; Volpe R; Candiani E; Toffoli G; D'Incalci M
Doxorubicin distribution in human breast cancer.
Cancer treatment reports 1987;71(12):1221-6.
-
1987: Capolongo L S; Balconi G; Ubezio P; Giavazzi R; Taraboletti G; Regonesi A; Yoder O C; D'Incalci M
Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent.
European journal of cancer & clinical oncology 1987;23(10):1529-35.
-
1987: Mannironi C; Rossi V; Biondi A; Ubezio P; Masera G; Barbui T; D'Incalci M
Histone H1(0) is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes.
Blood 1987;70(4):1203-7.
-
1987: Catapano C V; Broggini M; Erba E; Ponti M; Mariani L; Citti L; D'Incalci M
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Cancer research 1987;47(18):4884-9.
-
1987: Zanette M L; Tirelli U; Sorio R; Zadro D; Figoli F; Monfardini S; D'Incalci M
Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
Cancer chemotherapy and pharmacology 1987;20(1):67-70.
-
1987: Figoli F; Zanette M L; Tirelli U; Sorio R; Lestuzzi C; Urso R; Monfardini S; D'Incalci M
Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
Cancer chemotherapy and pharmacology 1987;20(3):239-42.
-
1986: D'Incalci M; Rossi C; Zucchetti M; Urso R; Cavalli F; Mangioni C; Willems Y; Sessa C
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
Cancer research 1986;46(5):2566-71.
-
1986: Colombo T; Broggini M; Vaghi M; Amato G; Erba E; D'Incalci M
Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
European journal of cancer & clinical oncology 1986;22(2):173-9.
-
1986: Farina P; Torti L; Urso R; Horton J K; Gescher A; D'Incalci M
Comparison of metabolism and activity of an aryldimethyltriazene and an aryldiethyltriazene.
Biochemical pharmacology 1986;35(2):209-15.
-
1985: Farina P; Benfenati E; Lassiani L; Nisi C; D'Incalci M
High-performance liquid chromatographic assay for the determination of p-(3,3-dimethyl-1-triazeno)benzoic acid in mouse plasma.
Journal of chromatography 1985;345(2):323-31.
-
1985: D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
Pharmacokinetics of teniposide in patients with ovarian cancer.
Cancer treatment reports 1985;69(1):73-7.
-
1984: Rossi C; Zucchetti M; Sessa C; Urso R; Mangioni C; D'Incalci M
Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.
Cancer chemotherapy and pharmacology 1984;13(3):211-4.
-
1983: D'Incalci M; Torti L; Damia G; Erba E; Morasca L; Garattini S
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Cancer research 1983;43(12 Pt 1):5674-80.
-
1983: Farina P; Benfenati E; Reginato R; Torti L; D'Incalci M; Threadgill M D; Gescher A
Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene.
Biomedical mass spectrometry 1983;10(8):485-8.
-
1983: Erba E; Ubezio P; Colombo T; Broggini M; Torti L; Vaghi M; D'Incalci M; Morasca L
Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1983;10(3):208-11.
-
1982: Farina P; Gescher A; Hickman J A; Horton J K; D'Incalci M; Ross D; Stevens M F; Torti L
Studies of the mode of action of antitumour triazenes and triazines--IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene.
Biochemical pharmacology 1982;31(10):1887-92.
-
1982: D'Incalci M; Erba E; Vaghi M; Morasca L
In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.
European journal of cancer & clinical oncology 1982;18(4):377-80.
-
1982: Colombo T; Broggini M; Torti L; Erba E; D'Incalci M
Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.
Cancer chemotherapy and pharmacology 1982;7(2-3):127-31.
-
1981: Colombo T; Torti L; D'Incalci M
Dose-dependent pharmacokinetics of PMM in the rat.
Cancer chemotherapy and pharmacology 1981;5(3):201-3.
-
1980: D'Incalci M; Erba E; Balconi G; Morasca L; Garattini S
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
British journal of cancer 1980;41(4):630-5.
-
1980: Morasca L; Balconi G; Erba E; D'Incalci M; Ottolenghi L; Salmona A; Garattini S
Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Oncology 1980;37(3):169-73.
Sign-in to see more
